KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Current Liabilities (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Total Current Liabilities data on record, last reported at $66.3 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 1.84% year-over-year to $66.3 million; the TTM value through Sep 2025 reached $66.3 million, down 1.84%, while the annual FY2024 figure was $61.4 million, 19.76% up from the prior year.
  • Total Current Liabilities reached $66.3 million in Q3 2025 per NKTR's latest filing, down from $71.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $140.0 million in Q3 2021 and bottomed at $50.7 million in Q2 2023.
  • Average Total Current Liabilities over 5 years is $79.1 million, with a median of $68.2 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: crashed 67.25% in 2021, then skyrocketed 35.35% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $85.2 million in 2021, then decreased by 19.95% to $68.2 million in 2022, then decreased by 24.83% to $51.3 million in 2023, then increased by 19.76% to $61.4 million in 2024, then rose by 8.05% to $66.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $66.3 million in Q3 2025, $71.4 million in Q2 2025, and $70.9 million in Q1 2025.